Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company is actively seeking to improve global health by developing superior vaccines that will be designed to prevent or hopefully treat some of the most common and deadly infectious diseases worldwide, announced on June 3, 2020, that they are appointing Halley E. Gilbert to its board of directors. Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte said that they are very excited that she is joining this family. He also said that she has the capability to bring over two decades of operational, transactional, and strategic leadership experience within the biotechnology industry.

NASDAQ: PCVX at will have a lot of benefit from her depth of expertise in this field as they continue to grow the company. Ms. Gilbert said that she is delighted to join the company Vaxcyte board at such an exciting time and she is looking forward to contributing all her experiences to help the company as they move toward a better tomorrow delivering the next generation of vaccines for worldwide diseases.

This next-generation vaccine company is trying to improve global health by developing superior and powerful vaccines specifically designed to prevent deadly infectious diseases worldwide. They also announced the pricing of their upsized initial public offerings of 15,625,000 shares at a public offering price of $16.00 per share. All of these shares are being offered by Vaxcyte, and all the gross proceeds of these offerings, although before deducting underwriting discounts and commissions, are totally payable by Vaxcyte and are a total of $250.0 million. This kind of share trading started on the Nasdaq Global Select Market on June 12, 2020, under “PCVX”.

Vaxcyte has also granted its underwriters a 30-day option to purchase up to any additional 2,343,750 shares of common stock they put forward at the public offering price with less underwriting discounts and commissions. This offering closed on June 16, 2020, subject to the point that the satisfaction of customers is above expectations. BofA Securities, Jefferies, and Evercore ISI are all acting as joint book-running managers for these offerings.

Cantor and Needham & Company are acting as co-managers for these offerings. The registration statements relating to these securities have become effective from June 11, 2020. These offerings are being made only by means of a prospectus. This press release does not constitute an offer that indicates selling or the solicitation of any kind of offers to buy these securities and neither will there be any sale of these securities in any other states.  You can check more stock news before you start to invest in stock app. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Author Since: Oct 17, 2018

Related Post